Eli Lilly anticipates regulatory approval for its weight-loss drug Zepbound in Japan by mid-2025, boosting its global ...

The FDA has decided to reconsider its previous decision that barred drug compounders from selling their versions of Eli Lilly ...

The FDA has agreed to revisit its decision to prevent compounders from selling versions of Eli Lilly's diabetes and weight ...

Morgan Stanley analyst Terence Flynn maintained a Hold rating on Prime Medicine, Inc. (PRME – Research Report) today and set a price ...

Daryl Brown, who was prescribed the antidepressant Seroxat in childhood because of his Tourette’s syndrome and OCD, tells ...

(Reuters) -The U.S. Food and Drug Administration on Friday agreed to reconsider a decision it made last month to bar drug ...

Morgan Stanley analyst Terence Flynn maintained a Hold rating on Organon (OGN – Research Report) today and set a price target of $18.00.